Biclonal gammopathy in a patient taking efalizumab for the treatment of psoriasis by Fthenakis, Antonia et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Dermatology Faculty Publications Dermatology
2013
Biclonal gammopathy in a patient taking efalizumab









Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_derm_facpubs
Part of the Dermatology Commons
This Journal Article is brought to you for free and open access by the Dermatology at Health Sciences Research Commons. It has been accepted for
inclusion in Dermatology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
Recommended Citation
Fthenakis, A., Wenk, K.S., Ehrlich, A., Aragon-Ching, J.B. (2013). Biclonal gammopathy in a patient taking efalizumab for the
treatment of psoriasis. Journal of Hematology and Thromboembolic Diseases, 1:106.
Journal of Hematology & 
Thromboembolic Diseases
Fthenakis et al., J Hematol Thromb Dis 2013, 1:2
http://dx.doi.org/10.4172/jhtd.1000106
 Review Article Open Access
Volume 1 • Issue 2 • 1000106
J Hematol Thromb Dis
ISSN:JHTD, an open access journal 
Biclonal Gammopathy in a Patient taking Efalizumab for the Treatment of 
Psoriasis
Antonia Fthenakis1, Kurt S Wenk2, Alison Ehrlich2 and Jeanny B Aragon-Ching3*
1The George Washington University Medical Center, School of Medicine, Washington DC, USA
2The George Washington University Medical Center, Department of Dermatology, Washington DC, USA
3The George Washington University Medical Center, Department of Medicine, Division of Hematology/Oncology, Washington DC, USA
Abstract
We report a patient who developed biclonal gammopathy of undetermined significance during treatment with 
efalizumab for psoriasis. This plasma cell disorder was found during the evaluation of the patient’s complaint of mild 
lower extremity paresthesia. The gammopathy spontaneously remitted following cessation of therapy and has not 
recurred to date. Given the increasing use and development of biological agents for the treatment of psoriasis and 
other disorders, this finding and the mechanisms by which it may have occurred is of clinical significance.
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Introduction
In cases of moderate to severe psoriasis that are refractory to other 
interventions, biological agents may serve as successful treatment 
options. One such bioengineered protein is efalizumab, which was 
approved by the FDA for the treatment of moderate to severe plaque 
psoriasis in 2003. It is a recombinant humanized monoclonal antibody 
targeted against CD11a, a component of leukocyte function associated 
antigen-1 (LFA-1) on T cells. LFA-1 plays an important role in T cell 
activation and migration, and its inhibition suppresses inflammatory 
responses involved in the pathogenesis of psoriasis [1]. Numerous 
phase III clinical trials have demonstrated the efficacy of efalizumab. 
However, the medication was withdrawn from the market in 2009 when 
it was linked to cases of progressive multifocal leukoencephalopathy 
(PML) that occurred in patients who had been using the drug for several 
years [2]. Other known side effects of efalizumab include infection, 
arthritis, rebound exacerbation of psoriasis, autoimmune hemolytic 
anemia, and immune-mediated thrombocytopenia [3]. In addition to 
PML, efalizumab has been associated with Guillain-Barre syndrome, 
and chronic inflammatory demyelinating polyneuropathy [4]. An 
association with monoclonal or biclonal gammopathy of undetermined 
significance (MGUS, BGUS) has been previously described in only 
one report to date [5]. We describe the case of a patient who developed 
BGUS during efalizumab treatment for psoriasis, which spontaneously 
remitted following cessation of the drug. 
Case Presentation
A 52 year-old female with psoriasis presented with a 6-month history 
of paresthesias affecting the first three toes of her lower extremities. 
Her medical history was significant for hypertension, hypothyroidism, 
and hyperlipidemia. She reported no new medications in the past year 
except for efalizumab (50 mg weekly subcutaneous injection), which 
was started 10 months prior to treat her psoriasis. Family history 
was significant for multiple sclerosis in her mother. Physical exam 
revealed numerous erythematous, scaly plaques involving her hands 
and feet. She displayed decreased sensation to light touch, pin prick, 
and temperature in her medial three toes, with mild impairment in 
proprioception. The rest of the exam was normal. 
An electromyelogram was performed that could not rule out a 
small-fiber neuropathy, and the patient was referred to rheumatology 
after having a positive ANA titer of 1:1280, total globulin 4.9 g/dL (1.5-
4.5 g/dL), and total protein 9.0 g/dL (6.0-8.5 g/dL). A serum protein 
electrophoresis (SPEP) showed a biclonal gammopathy with gamma 
globulins measuring 2.9 g/dL (0.6-1.6 g/dL), with 2 paraprotein 
peaks at 0.9 g/dL and 1 g/dL. Corresponding serum immunofixation 
electrophoresis (IFE) revealed the presence of an IgG kappa and free 
lambda light chain paraprotein. These electrophoresis studies were 
performed approximately 8 months after her initial presentation as part 
of the continuing diagnostic workup. The patient was documented to 
have a normal SPEP during the initial workup, with a gamma globulin 
level of 1.5 g/dL (0.6-1.6 g/dL). Additional laboratory findings included: 
free kappa/lambda ratio: 1.85 (0.26-1.65), beta-2 (β2) microglobulin: 
3.26 mg/L (≤ 2.51 mg/L), IgM level: 71 mg/dL (48-271 mg/dL), IgG: 
2914 mg/dL (694-1618 mg/dL), and IgA: 228 mg/dL (81-463 mg/dL). 
Skeletal survey, cytogenetics, and fluorescence-in-situ hybridization 
(FISH) for myeloma were all negative, and a bone marrow aspiration 
and biopsy showed minimal plasmacytosis with up to 5% of plasma 
cells.
The patient was diagnosed with biclonal gammopathy and was 
followed every 3 months for repeat laboratory work and annual skeletal 
surveys. Efalizumab was discontinued at the time of diagnosis after 
18 months of therapy. The patient was later treated with excimer laser 
and topical steroids for psoriasis. Her SPEP biclonal spike, IgG levels, 
β2 microglobulin, and free kappa/lambda ratio gradually normalized 
within 12 months after stopping efalizumab. The paraprotein on IFE 
was no longer detectable by 21 months. She did, however, continue to 
have persistent, unchanged paresthesias in her lower extremities. 
Discussion
Monoclonal gammopathy of undetermined significance (MGUS) 
is the most common plasma cell disorder. It is distinguished from 
multiple myeloma by a serum monoclonal protein concentration lower 
than 3.0 g/dL, fewer than 10% plasma cells in the bone marrow, and 
the absence of hypercalcemia, lytic bone lesions, or renal insufficiency. 
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Biclonal gammopathy of unknown significance (BGUS), which is the 
simultaneous appearance of 2 monoclonal proteins, occurs rarely, with 
an incidence of about 1% of all gammopathies [6]. Although limited 
data for BGUS exists in the literature, it appears to behave and is treated 
similarly to MGUS [7]. 
While clinically asymptomatic, MGUS is a known precursor of 
multiple myeloma (MM), primary amyloidosis, and Waldenstrom 
macroglobulinemia [8]. The prevalence of MGUS increases with age, 
occurring in 3.2% of subjects ≥ 50 and 5.3% of those ≥ 70 according 
to a large epidemiological study in Olmsted County, Minnesota 
[9]. However, reports to date have not determined an excess risk in 
patients with psoriasis [10,11]. The current standard of care of MGUS 
is observation without therapy. As this condition is thought to be the 
first pathogenetic step in the development of MM, patients generally 
require lifelong annual follow-up to detect malignant transformation. 
The average rate of progression to MM or a related malignancy is 1% 
per year [12]. MM is an incurable disease, and the average survival with 
current treatment is between 3 and 4 years from time of diagnosis. 
We describe the development of BGUS in an individual treated 
with efalizumab. The likelihood that the drug played a role in our 
patient’s gammopathy is supported by the gradual resolution of her 
abnormal SPEP and IFE studies following its discontinuation, as well as 
the absence of known risk factors for MGUS or MM. The disappearance 
of an M-protein without a known cause or intervention is exceedingly 
rare [8]. In a study by Kyle et al. (1981) spontaneous resolution 
occurred in only 27 of 1384 patients (2%) diagnosed with MGUS, most 
of whom had a small initial monoclonal protein size that could not 
be measured on densitometer tracings [7]. Prignano et al. described 
the development of either monoclonal or biclonal gammopathy in 12 
patients receiving efalizumab treatment which progressively declined 
following discontinuation of the drug [5]. Only one known study prior 
to Prignano et al. has demonstrated a potential association between the 
use of medication and MGUS. In this population-based case control 
study, the authors found an increased risk of MM in individuals with 
a history of taking prednisone, insulin, or anti-gout medication [13]. 
Interestingly, MGUS has been associated with the presence of 
peripheral neuropathy, with symptoms including foot numbness and 
paresthesias as experienced by our patient. In addition, individuals 
may have aching discomfort, gait ataxia, and sensory deficits in touch 
and vibration [14]. MGUS-related neuropathies occurs more often in 
association with IgM paraproteins (60%), followed by IgG (30%) and 
IgA (10%), with increasing levels of detection obtained with IFE [14,15]. 
In contrast, only several case reports have described an association 
of efalizumab with polyneuropathy, all of which were inflammatory 
demyelinating neuropathies [16]. It is unclear whether the paresthesias 
in our patient were related to her gammopathy, as her symptoms have 
persisted despite BGUS resolution.
The exact mechanism by which efalizumab may have contributed 
to the development of BGUS is unknown. While the etiology of 
both MGUS and MM remain unclear, it has been suggested that 
environmental factors, genetic changes, and cytokines IL-1, IL-6, and 
TNF-α may be involved [12]. In addition, increased expression of 
adhesion molecules such as CD54, CD106, CD49d, and CD11a may 
play an important role in binding of MM cells to bone marrow stromal 
cells, promoting IL-6 secretion and proliferation of tumor cells [17]. 
LFA-1 expressed by MM cells appears to play an important role in 
disease pathogenesis, and efalizumab binding to the CD11a component 
of LFA-1 on predisposed B cells may alter cell proliferation, cytokine 
production, or survival pathways to promote clonal expansion [18]. 
Efalizumab’s immunosuppressant effect may also contribute to the 
development of MGUS, as reports exist of MGUS developing secondary 
to immunodeficiency states and immune dysregulation (such as 
acquired immunodeficiency syndrome or after organ transplantation) 
that have resolved with immune system recovery [19,20]. It is also 
possible that detection of efalizumab itself, an IgG1 kappa antibody, 
or development of a low-titer antibody to efalizumab, may have been 
detected and contributed to the biclonal gammopathy. However, 
pharmacokinetic studies indicate that the mean time to eliminate 
efalizumab after the last steady-state dose is about 25 days making this 
a less likely etiology [21].
Conclusion
We describe an association between the biological agent efalizumab 
and MGUS. While efalizumab has already been withdrawn from the 
market, the exact mechanism between development of gammopathy 
and this agent is unclear, and this association may have important 
implications given the use of other biological agents that are currently 
on the market and in development for the treatment of psoriasis and 
other connective tissue disorders. It is important for dermatologists 
to be aware of this potential side effect, especially when using newer 
biological agents that may target similar pathways. 
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